HR+/HER2+ breast cancer remains the predominant type of breast cancer with the HER2 signaling pathway, requiring anti-HER2+ therapy followed by a combination of endocrine therapies depending on HR expression. The gene discussed is ERBB2; the disease is breast carcinoma.